[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642827":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":28,"locations":29,"responsibleParty":49,"collaborators":51,"id":55,"slug":28,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":28,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":28,"enrollmentInfo":63,"targetDuration":28,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":32,"whyStopped":28,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Cellio Therapeutics Inc","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL","C.001Low Dose",[13],"Biological: Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2","C.001 Medium Dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arm 3","C.001 High Dose",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","Injection","C.001 administered once via subretinal injection",[9,15,19],null,[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Clinical Trial Site 1","RECRUITING","Beverly Hills","California","90210","United States",{"type":38,"coordinates":39},"Point",[40,41],-118.40036,34.07362,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":28,"email":48},"Clinical Trial Administer","CONTACT","regulatory@celliotherapeutics.","regulatory@celliotherapeutics.com",{"type":50,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[52],{"name":53,"class":54},"California Institute for Regenerative Medicine (CIRM)","OTHER","100642827",false,"NCT07594236","Phase 1 Study of C.001 in Retinal Degeneration","A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of retinal disease associated with retinal pigment epithelium degeneration (e.g., geographic atrophy or Stargardt disease)\n* Visual acuity within protocol-defined limits\n* Stable ocular condition prior to enrollment\n* Medically suitable for ophthalmic surgery and anesthesia\n* Willingness to comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Active or prior choroidal neovascularization (CNV)\n* Recent myocardial infarction or significant uncontrolled cardiovascular disease\n* Uncontrolled glaucoma\n* Significant ocular inflammatory disease\n* Recent intraocular surgery within protocol-defined timeframe\n* Active systemic infection\n* Poorly controlled diabetes (e.g., HbA1c \\>8.5%)\n* Participation in another investigational study within 3 months prior to screening","ALL","18 Years",{"count":64,"type":65},15,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.\n\nParticipants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner.\n\nThe primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.",[71,72,73,74],"Geographic Atrophy","Stargardt Disease","RPE-mediated Maculopathy","Age Related Macular Degeneration",[76,77,78],"macular degeneration","macular distrophy","C.001","2026-06-10",{"date":81,"type":82},"2026-06-12","ACTUAL",{"date":84,"type":82},"2026-04-07",{"date":86,"type":65},"2029-12-31",{"name":5,"class":6},1]